M&A Deal Summary

Celltrion Acquires Takeda Pharmaceutical - Primary Care Product Assets

On November 30, 2020, Celltrion acquired life science company Takeda Pharmaceutical - Primary Care Product Assets from Takeda for 278M USD

Acquisition Highlights
  • This is Celltrion’s 1st transaction in the Life Science sector.
  • This is Celltrion’s largest (disclosed) transaction.
  • This is Celltrion’s 1st transaction in Japan.

M&A Deal Summary
Date 2020-11-30
Target Takeda Pharmaceutical - Primary Care Product Assets
Sector Life Science
Buyer(s) Celltrion
Sellers(s) Takeda
Deal Type Divestiture
Deal Value 278M USD

Target

Takeda Pharmaceutical - Primary Care Product Assets

Osaka, Japan
Takeda Pharmaceutical Co. Ltd. - Primary Care 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Edarbi (hypertension) which were developed for the global market, as well as OTC (Over-the-counter) products well known to consumers such as Whituben (cold remedy). Nesina and Edarbi.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Celltrion

Incheon, South Korea
Category Company
Founded 2002
Sector Life Science
Employees2,391
Revenue 2.18T KRW (2023)
DESCRIPTION

Celltrion is a biopharmaceutical company specializing in the development of “biosimilars” for monoclonal antibody drugs. Celltrion provides biosimilars for auto-immune diseases and various cancers; generic pharmaceuticals; and covid-19 test kits. Celltrion was incorporated in 2002 and is based in Incheon, South Korea.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Japan) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

Takeda

Tokyo, Japan
Category Company
Founded 1781
Sector Life Science
Employees47,347
Revenue 4.03T JPY (2023)
DESCRIPTION
Takeda's corporate headquarters in Tokyo, Japan.
Takeda's corporate headquarters in Tokyo, Japan.

Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was originally established in 1781 and is based in Tokyo, Japan.

DEAL STATS #
Overall 6 of 6
Sector (Life Science) 3 of 3
Type (Divestiture) 6 of 6
Country (Japan) 5 of 5
Year (2020) 3 of 3
Size (of disclosed) 3 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-16 TachoSil

Osaka, Japan

TachoSil provides surgical patches used for bleeding control.

Sell $564M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-09 Maverick Therapeutics

Brisbane, California, United States

Maverick Therapeutics is a biopharmaceutical company pioneering conditionally active bispecific T-cell targeted immunotherapies. Maverick Therapeutics provides T cell therapy to solid tumor cancers by focusing deep integrated expertise in drug development to design and deliver a pioneering immunotherapy platform. Maverick’s highly innovative COBRA™ therapeutic platform is the most mature, conditionally active bispecific T cell engaging platform designed to eliminate solid tumors. With COBRA, T cell activation and resulting cell killing only take place where it is needed – in tumors. This unique design delivers the long-sought trifecta in cancer care; high specificity, high potency, and reduced toxicity. Maverick Therapeutics was founded in 2016 and is based in Brisbane, California.

Buy $525M
Mergr

Product

Company

Legal